Is glutathione injection indicated for the treatment of liver disease?

Glutathione Injection Has No Established Role in Liver Disease Treatment

Glutathione injection is not indicated for the treatment of liver disease based on current clinical practice guidelines. The only established antioxidant therapy with strong evidence for liver disease is N-acetylcysteine (NAC), which is recommended specifically for acute liver failure, not glutathione 1.

Evidence-Based Recommendations

What Guidelines Actually Support

N-acetylcysteine (NOT glutathione) is the recommended antioxidant:

• GRADE 1+ recommendation: NAC should be initiated immediately in acetaminophen-induced acute liver failure 1
• GRADE 2+ recommendation: NAC may improve morbidity and mortality in acute liver failure of any etiology 1
• NAC improves transplant-free survival (64% vs 26%, OR = 4.81) and overall survival (76% vs 59%, OR = 2.30) in non-acetaminophen acute liver failure 1

Why Glutathione Is Not Recommended

Critical distinction: NAC works by restoring intracellular glutathione levels through metabolic pathways, but direct glutathione administration faces fundamental problems:

1. No guideline support: Major liver disease guidelines (EASL, AASLD, BSG) from 2016-2025 make no recommendations for glutathione therapy 2, 3, 4, 5, 6

2. FDA labeling limitation: Glutathione is only FDA-approved as an intraocular irrigating solution component during eye surgery—explicitly labeled "NOT FOR INJECTION OR INTRAVENOUS INFUSION" 7

3. Weak research evidence: While small studies show biochemical improvements in liver enzymes (ALT, AST) with IV glutathione in chronic fatty liver disease 8, 9, these are old (1991-1995), small sample size studies that have never been validated in rigorous clinical trials

Research Evidence Analysis

Recent research (2024-2026) reveals important nuances but does not change clinical recommendations:

• A 2026 cluster analysis of 466 patients found glutathione supplementation may benefit only a specific phenotype: advanced unstable cirrhosis with active systemic inflammation (10.9% of patients), not stable compensated disease 10
• Even in this "ideal responder" subgroup, mortality remained high (23.5%) despite MELD score improvements 10
• Systematic reviews confirm glutathione depletion occurs in NAFLD/MASLD but note heterogeneous measurement methods and lack of standardized therapeutic protocols 11, 12

Clinical Algorithm

For acute liver failure:

1. Initiate N-acetylcysteine immediately (not glutathione)
2. Standard NAC dosing: IV infusion per established protocols
3. Start early—benefit greatest in grades I-II encephalopathy 1

For chronic liver disease (cirrhosis, NAFLD, alcoholic liver disease):

1. No role for glutathione injection in routine management
2. Focus on disease-specific interventions: alcohol cessation, weight loss, diabetes control, treatment of underlying etiology 4, 13, 6
3. Consider NAC only in research settings or acute-on-chronic liver failure contexts

Common Pitfalls to Avoid

• Do not confuse glutathione with N-acetylcysteine: They are different molecules with different evidence bases
• Do not use off-label IV glutathione: The FDA-approved formulation is for ophthalmic use only 7
• Do not rely on old, small studies: The 1990s Italian studies 8, 9 showing enzyme improvements have never been replicated in adequately powered trials
• Beware of indiscriminate antioxidant use: Recent evidence suggests only specific inflammatory phenotypes might respond, and even then, clinical benefit is uncertain 10

The precision medicine approach suggested by recent research 10 requires prospective validation before clinical implementation—currently, there is insufficient evidence to recommend glutathione therapy for any liver disease indication.